$92.19
1.3%
Price vs. AI Score (Last 150 days)
Data gathered: December 1
Data gathered: December 1
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | 117 -3.3% |
|
| Sentiment | 86 -1.1% |
|
| Webpage traffic | 41,000 43.9% |
|
| Employee Rating | 83 0% |
|
| Google Adspend | $2,306 692.4% |
|
| Google Trends | 0% |
|
| Linkedin Employees | 3,239 N/A |
|
| Patents | 73 0% |
|
| 4chan Mentions | 0% |
|
| Facebook Engagement | 3 50% |
|
| Facebook followers | 6,038 0% |
|
| Stocktwits Mentions | 2 100% |
|
| Stocktwits Subscribers | 5,037 -0.1% |
|
| Youtube Subscribers | 1,330 0% |
|
| Instagram Followers | 4,219 N/A | N/A |
| News Mentions | -100% |
|
| Reddit Mentions | 0% |
|
| Business outlook | 79 0% |
|
In the news
Analysts Are Bullish on These Healthcare Stocks: UnitedHealth (UNH), Alnylam Pharma (ALNY)November 29 - TipRanks |
|
 |
Elfun Trusts Sheds Qualcomm in Q3, Embraces New HoldingsNovember 29 - Yahoo |
Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031November 29 - GlobeNewswire |
|
 |
Pro Research: Wall Street eyes BioMarin's strategic growthNovember 28 - Investing.com |
 |
BioMarin secures hemophilia gene therapy coverage in GermanyNovember 28 - Yahoo |
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN for Severe Hemophilia A in GermanyNovember 28 - Finnhub |
|
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Price | $92.19 |
| Target Price | Sign up |
| Market Cap | $16.9B |
| Dividend Yield | 0.0371 |
| Industry | Biotechnology |
Similar companies
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 578M | 125M | 453M | 40M | 71M |
| Q2 '23 | 592M | 128M | 463M | 56M | 100M |
| Q1 '23 | 586M | 127M | 460M | 51M | 87M |
| Q4 '22 | 506M | 127M | 379M | -250,000 | 11M |
| Q3 '22 | 501M | 116M | 384M | -6.7M | 28M |
Insider Transactions
| Ajer Jeffrey Robert filed to sell 60,804 shares at $90. August 17 '23 |
| FUCHS HENRY J filed to sell 176,187 shares at $90.4. August 11 '23 |
| Guyer Charles Greg filed to sell 40,041 shares at $93.3. August 10 '23 |
| BIENAIME JEAN JACQUES filed to sell 422,732 shares at $88.3. August 9 '23 |
| Davis George Eric filed to sell 69,474 shares at $89.4. August 9 '23 |
Read more about Biomarin Pharmaceutical and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google adspend, google trends, linkedin employees, patents, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, youtube subscribers, instagram followers, news mentions, reddit mentions, business outlook.